Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov-Dec;32(6):e165-e166.
doi: 10.1097/DER.0000000000000809.

Results of Switching From Tofacitinib to Upadacitinib in Patients With Atopic Dermatitis: A Retrospective Medical Record Review

David X Gao  1 , Jared S Kahn, Stephanie R Cohen, Delaney M Griffiths, Kristin Fiumara, Anh Lam, Nicole Dumont, David Rosmarin
Affiliations

Results of Switching From Tofacitinib to Upadacitinib in Patients With Atopic Dermatitis: A Retrospective Medical Record Review

David X Gao et al. Dermatitis. 2021 Nov-Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

D.R. has received honoraria as a consultant for AbbVie, Abcuro, AltruBio, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Concert, Dermavant, Dermira, Incyte, Janssen, Kyowa Kirin, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharmaceuticals, UCB, and Viela Bio; has received research support from AbbVie, Amgen, Bristol Meyers Squibb, Celgene, Dermira, Galderma, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer, and Regeneron Pharmaceuticals, Inc; and has served as a paid speaker for AbbVie, Amgen, Celgene, Janssen, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc, and Sanofi. The remaining authors have no funding or conflicts of interest to declare.

References

    1. Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020;145(3):877–884. doi:10.1016/j.jaci.2019.11.025. - DOI
    1. Suh TP, Ramachandran D, Patel V, et al. Product of investigator global assessment and body surface area (IGAxBSA): a practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children. J Am Acad Dermatol 2020;82(5):1187–1194. doi:10.1016/j.jaad.2020.01.023. - DOI
    1. AbbVie. RINVOQTM (upadacitinib) achieved superiority versus DUPIXENT® (dupilumab) for primary and all ranked secondary endpoints in phase 3b head-to-head study in adults with atopic dermatitis [press release]. December 10, 2020. Available at: https://news.abbvie.com/news/press-releases/rinvoq-upadacitinib-achieved.... Accessed February 5, 2021.
    1. Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 2015;73(3):395–399.
    1. Mohamed MF, Beck D, Camp HS, et al. Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib. J Clin Pharmacol 2020;60(2):188–197.

MeSH terms

LinkOut - more resources